ZR2 Sequential Immunochemotherapy for Newly Treated MCL
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
Recruiting · NCT05992597 · Registry updated 2023-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ZR2 Sequential Immunochemotherapy for Newly Treated MCL | Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma | Recruiting | Phase 2 | 2023-09-21 | NCT05992597 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhejiang Cancer Hospital | 142 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Zhejiang Cancer Hospital | Hangzhou | China | 164 |